GO:0045747 positive regulation of Notch signaling pathway: Activation Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045747 describes any process that activates or increases the frequency, rate or extent of the Notch signaling pathway, a conserved cell-cell communication system.
• Positive regulation of Notch signaling is driven by ligand-receptor interactions, proteolytic cleavage of NOTCH receptors, and nuclear co-activator assembly.
• Key positive regulators include ADAM17, RBPJ, TRIM59, and GRWD1, which enhance Notch pathway activity in cancer and immune contexts.
• Dysregulated positive regulation of Notch signaling contributes to gastric cancer, pancreatic cancer, hepatocellular carcinoma, and Epstein-Barr virus-induced infectious mononucleosis.
• Notch signaling positively regulates CD8+ T cell responses and antitumor immunity, making it a target for immuno-oncology research.
• CRISPR knockout, point mutation, knock-in, and overexpression models are essential to dissect causal roles of positive regulators in Notch signaling.
Description
The Notch signaling pathway is an evolutionarily conserved intercellular communication system that controls cell fate decisions, proliferation, and differentiation across metazoans. GO:0045747, positive regulation of Notch signaling pathway, refers to any process that activates or increases the frequency, rate or extent of this pathway. Understanding how Notch signaling is positively regulated is critical because excessive or mislocalized activation drives multiple cancers and immune disorders. Positive regulators of Notch signaling include extracellular ligands, proteases such as ADAM17, and nuclear co-activators like RBPJ, which together amplify signal transduction. In gastric cancer, GRWD1 overexpression activates Notch signaling via up-regulation of ADAM17, promoting tumor progression. In pancreatic cancer, a TRIM59/RBPJ positive feedback circuit confers gemcitabine resistance by activating Notch signaling. These examples illustrate that positive regulation of Notch signaling is not a single event but a network of molecular interactions that can be hijacked in disease. Researchers studying development, immunity, and cancer need precise tools to manipulate and measure this pathway. This article integrates QuickGO definitional data with verified PubMed literature to provide a research-grade overview of GO:0045747, its mechanisms, key genes, disease links, and experimental methods.
positive regulation of Notch signaling pathway At A Glance
| GO ID | GO:0045747 |
|---|---|
| GO term | positive regulation of Notch signaling pathway |
| Ontology | biological_process |
| Synonym | activation of Notch signaling pathway; stimulation of Notch signaling pathway; upregulation of Notch signaling pathway; positive regulation of Notch signalling pathway; positive regulation of N signaling pathway |
| Major function | Increases the frequency, rate or extent of Notch signaling, affecting cell fate, proliferation, differentiation, and immune responses |
| Related pathways | Notch signaling pathway (GO:0007219); Notch receptor processing; CD8+ T cell activation |
| Disease relevance | Gastric cancer, pancreatic cancer, hepatocellular carcinoma, Epstein-Barr virus-induced infectious mononucleosis, alloreactivity |
| Experimental models | CRISPR knockout, point mutation, knock-in, overexpression cell models; CRISPR library screening |
What Is GO:0045747?
GO:0045747 is a biological process term defined as any process that activates or increases the frequency, rate or extent of the Notch signaling pathway. It encompasses molecular events that enhance Notch receptor activation, ligand presentation, proteolytic processing, nuclear transduction, or downstream transcriptional output. Synonyms include activation of Notch signaling pathway, stimulation of Notch signaling pathway, and upregulation of Notch signaling pathway.
Why Is positive regulation of Notch signaling pathway Important in Cell Biology?
Positive regulation of Notch signaling is essential for normal development and tissue homeostasis, but its dysregulation is a hallmark of many cancers and immune pathologies. In gastric cancer, GRWD1 overexpression activates Notch signaling through ADAM17 up-regulation, promoting tumor progression. In pancreatic cancer, a TRIM59/RBPJ positive feedback circuit activates Notch signaling and confers gemcitabine resistance. Notch signaling also regulates CD8+ T cell exhaustion and antitumor immunity in hepatocellular carcinoma. In infectious mononucleosis caused by Epstein-Barr virus, Notch signaling pathway components are altered in adult patients. Furthermore, Notch signaling influences alloreactivity in transplantation and early pregnancy in mice. Thus, understanding GO:0045747 is critical for developing targeted therapies and immunomodulatory strategies.
• Drives cancer progression in gastric cancer via GRWD1-ADAM17-Notch axis.
• Confers chemoresistance in pancreatic cancer through TRIM59/RBPJ feedback.
• Regulates CD8+ T cell exhaustion and antitumor immunity in hepatocellular carcinoma.
• Modulates immune responses in Epstein-Barr virus-induced infectious mononucleosis.
• Influences alloreactivity in transplantation settings.
• Plays a role in early pregnancy and embryonic development in mice.
• Down-regulation of Notch signaling induces apoptosis in lung squamous cell carcinoma cells, highlighting its pro-survival role.
• Serves as a therapeutic target for Notch inhibitors and activators in oncology and immunology.
• Provides a paradigm for understanding cell-cell communication in tissue homeostasis.
• Enables CRISPR-based functional genomics to identify novel positive regulators.
What Happens During positive regulation of Notch signaling pathway?
Ligand-receptor engagement and activation
In simple terms: A signal from one cell binds to a receptor on a neighboring cell, turning the pathway on.
Positive regulation of Notch signaling begins when Notch ligands (e.g., DLL1, DLL4, JAG1, JAG2) on a signal-sending cell bind to NOTCH receptors (NOTCH1-4) on a signal-receiving cell. This interaction triggers conformational changes that expose cleavage sites. In early pregnancy in mice, Notch signaling pathway members show dynamic expression, indicating active ligand-receptor engagement during development. Positive regulators can increase ligand availability or receptor sensitivity, thereby enhancing pathway activation.
Proteolytic cleavage of NOTCH receptors
In simple terms: The receptor is cut in two steps, releasing the intracellular part that moves to the nucleus.
Upon ligand binding, NOTCH is cleaved by ADAM metalloproteases (e.g., ADAM17) at the S2 site, followed by gamma-secretase cleavage at the S3 site, releasing the Notch intracellular domain (NICD). GRWD1 overexpression up-regulates ADAM17, promoting this cleavage and activating Notch signaling in gastric cancer. This proteolytic cascade is a key point of positive regulation, as increased ADAM17 activity amplifies signal transduction.
Nuclear translocation and transcriptional complex assembly
In simple terms: The released receptor piece enters the nucleus and switches on target genes.
NICD translocates to the nucleus and assembles a transcriptional activation complex with RBPJ (CSL) and co-activators such as MAML1 and p300. In pancreatic cancer, TRIM59 forms a positive feedback circuit with RBPJ, enhancing Notch target gene expression and gemcitabine resistance. This nuclear step is a major node for positive regulation, as increased RBPJ activity or co-activator recruitment boosts pathway output.
Feedback amplification and crosstalk
In simple terms: The pathway can boost itself or interact with other signals to stay active.
Positive regulation of Notch signaling often involves feedback loops. For example, TRIM59/RBPJ forms a positive feedback circuit that sustains Notch activation in pancreatic cancer. In hepatocellular carcinoma, Notch signaling is linked to CD8+ T cell exhaustion, suggesting crosstalk with immune signaling pathways. Such feedback mechanisms can lock cells into a Notch-high state, contributing to therapy resistance.
Downstream effects on cell fate and immunity
In simple terms: Turning on Notch changes what cells do, including how immune cells fight tumors.
Activated Notch signaling regulates target genes such as HES1 and HEY1, influencing cell proliferation, differentiation, and survival. In CD8+ T cells, Notch signaling promotes antitumor immunity but can also drive exhaustion in hepatocellular carcinoma. Down-regulation of Notch signaling induces apoptosis in lung squamous cell carcinoma cells, underscoring its pro-survival role. Thus, positive regulation of Notch signaling has context-dependent effects on cell fate and immune function.
Key Genes Involved in GO:0045747 positive regulation of Notch signaling pathway
The following genes and proteins are experimentally validated participants in positive regulation of Notch signaling, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NOTCH1 | Notch receptor; undergoes proteolytic cleavage to release NICD | Core receptor in Notch signaling; target for knockout and point mutation studies |
| NOTCH2 | Notch receptor paralog | Modulates Notch signaling in development and cancer |
| ADAM17 | Metalloprotease that cleaves NOTCH at S2 site | Up-regulated by GRWD1 to activate Notch in gastric cancer |
| RBPJ | Nuclear DNA-binding transcription factor for Notch targets | Forms positive feedback with TRIM59 in pancreatic cancer |
| TRIM59 | E3 ubiquitin ligase; stabilizes RBPJ | Drives gemcitabine resistance via Notch activation |
| GRWD1 | Glutamate-rich WD repeat containing 1; up-regulates ADAM17 | Promotes gastric cancer progression via Notch activation |
| MAML1 | Mastermind-like transcriptional co-activator | Enhances Notch target gene expression |
| DLL1 | Notch ligand | Activates Notch in signal-receiving cells |
| DLL4 | Notch ligand | Regulates angiogenesis and Notch activation |
| JAG1 | Notch ligand | Activates Notch signaling in development and cancer |
| JAG2 | Notch ligand | Modulates Notch signaling in immune cells |
| HES1 | Notch target gene; transcriptional repressor | Readout of Notch pathway activation |
| HEY1 | Notch target gene | Marker of Notch activation |
| CD8A | T cell co-receptor | Linked to Notch signaling in hepatocellular carcinoma immunity |
| PSEN1 | Gamma-secretase subunit | Cleaves NOTCH to release NICD |
| NCSTN | Gamma-secretase subunit | Required for Notch proteolysis |
| FBXW7 | E3 ubiquitin ligase that degrades NICD | Negative regulator of Notch; its loss enhances Notch signaling |
How Is positive regulation of Notch signaling pathway Regulated?
Positive regulation of Notch signaling is controlled at multiple levels. Extracellularly, ligand availability and receptor glycosylation modulate activation. Intracellularly, proteolytic cleavage by ADAM17 and gamma-secretase is rate-limiting and can be enhanced by proteins such as GRWD1. Nuclear co-activator recruitment, including RBPJ and MAML1, is amplified by TRIM59 in pancreatic cancer. Negative regulators such as FBXW7 degrade NICD, and their loss can further enhance Notch signaling. In immune contexts, Notch signaling is regulated during CD8+ T cell activation and exhaustion. Additionally, Notch signaling components are dynamically expressed during early pregnancy in mice, indicating hormonal or developmental regulation.
positive regulation of Notch signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| GRWD1 | Gastric cancer progression via ADAM17-Notch axis | Knockout or overexpression in gastric cancer cell lines |
| TRIM59 | Pancreatic cancer gemcitabine resistance via RBPJ-Notch feedback | Knockout and point mutation in pancreatic cancer cells |
| RBPJ | Pancreatic cancer chemoresistance; Notch transcriptional activation | Knock-in of tagged RBPJ for ChIP-seq |
| CD8A | Hepatocellular carcinoma immune exhaustion | Overexpression in T cell lines or primary T cells |
| NOTCH1 | Lung squamous cell carcinoma apoptosis resistance | Knockout and point mutation in lung cancer cells |
Cancer progression and chemoresistance
Positive regulation of Notch signaling is oncogenic in multiple cancers. In gastric cancer, GRWD1 overexpression activates Notch signaling via ADAM17 up-regulation, promoting tumor progression. In pancreatic cancer, a TRIM59/RBPJ positive feedback circuit activates Notch signaling and confers gemcitabine resistance. In hepatocellular carcinoma, Notch signaling is associated with CD8+ T cell exhaustion and poor prognosis. Down-regulation of Notch signaling induces apoptosis in lung squamous cell carcinoma cells, confirming its pro-survival role.
Immune regulation and infectious disease
Notch signaling positively regulates CD8+ T cell responses and antitumor immunity. In hepatocellular carcinoma, Notch signaling is linked to CD8+ T cell exhaustion, suggesting a dual role in immunity. In adult patients with Epstein-Barr virus-induced infectious mononucleosis, Notch signaling pathway components are altered, indicating a role in viral immune responses. Notch signaling also influences alloreactivity in transplantation, affecting graft-versus-host disease.
Developmental and reproductive biology
Notch signaling is essential for early pregnancy in mice, with dynamic expression of pathway members during embryo implantation. Positive regulation of Notch signaling contributes to cell fate decisions in development, and its dysregulation can lead to developmental abnormalities.
From positive regulation of Notch signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does GRWD1 causally activate Notch signaling in gastric cancer? | GRWD1 knockout and overexpression in gastric cancer cell lines |
| Does TRIM59/RBPJ feedback drive gemcitabine resistance? | TRIM59 knockout and RBPJ point mutation in pancreatic cancer cells |
| How does Notch signaling affect CD8+ T cell exhaustion? | CD8A overexpression and NOTCH1 knockout in T cells |
| What is the role of ADAM17 in Notch activation? | ADAM17 knockout and knock-in of catalytically dead mutant |
| Does Notch signaling regulate early pregnancy? | Conditional knockout of Notch components in mouse models |
| Can Notch activation be monitored in live cells? | Knock-in of fluorescent reporter into HES1 locus |
How to Study the positive regulation of Notch signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcript changes | Identify Notch target gene expression after GRWD1 manipulation |
| Western blot | Protein levels of NICD, ADAM17, RBPJ | Assess Notch cleavage and pathway activation |
| Co-immunoprecipitation | Protein-protein interactions | Map TRIM59/RBPJ complex |
| Luciferase reporter | Notch transcriptional activity | Measure positive regulation in cell lines |
| Immunofluorescence | NICD nuclear localization | Visualize Notch activation |
| CRISPR knockout | Loss-of-function phenotypes | Validate GRWD1 or TRIM59 as positive regulators |
| CRISPR knock-in | Tagged protein expression | Track RBPJ or NOTCH1 dynamics |
| Flow cytometry | CD8+ T cell activation/exhaustion markers | Study Notch role in antitumor immunity |
Transcriptomic and pathway analysis
RNA-seq and pathway enrichment analysis can identify changes in Notch target genes such as HES1 and HEY1 upon manipulation of positive regulators. In hepatocellular carcinoma, transcriptomic profiling linked Notch signaling to CD8+ T cell exhaustion signatures.
Proteomic and interactomic approaches
Co-immunoprecipitation and mass spectrometry can map interactions between RBPJ, TRIM59, and other co-activators in the Notch transcriptional complex. Proteolytic cleavage of NOTCH can be assessed by Western blot for NICD.
Imaging and reporter assays
Luciferase reporters driven by Notch-responsive elements (e.g., CSL-luciferase) measure pathway activity. Immunofluorescence can visualize NICD nuclear translocation and ligand-receptor engagement.
Functional genomics and CRISPR screening
CRISPR knockout screens can identify novel positive regulators of Notch signaling. For example, targeting GRWD1 or TRIM59 validates their role in Notch activation and cancer phenotypes. Point mutation and knock-in models allow precise dissection of catalytic and interaction domains.
How CRISPR Can Be Used to Study GO:0045747 positive regulation of Notch signaling pathway
Knockout
CRISPR knockout of positive regulators such as GRWD1 or TRIM59 reduces Notch signaling and reverses cancer phenotypes, validating their causal role. Knockout of NOTCH1 in lung squamous cell carcinoma cells induces apoptosis, confirming Notch pro-survival function.
Point Mutation
Point mutations in catalytic domains of ADAM17 or RBPJ can dissect which residues are required for Notch activation. For example, mutation of the RBPJ DNA-binding domain abolishes Notch target gene expression.
Knock-in
Knock-in of fluorescent or epitope tags into endogenous NOTCH1 or RBPJ loci enables real-time tracking of Notch activation and complex assembly. Knock-in of reporter genes into HES1 allows monitoring of pathway activity.
Overexpression
Overexpression of GRWD1 or TRIM59 activates Notch signaling and promotes tumor progression or chemoresistance, providing gain-of-function evidence. Overexpression of CD8A in T cells can modulate Notch-driven exhaustion.
How EDITGENE Supports positive regulation of Notch signaling pathway Research
Researchers studying positive regulation of Notch signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activation or merely correlated with it. EDITGENE provides CRISPR-based cell model services to enable such causal studies.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of Notch signaling pathway research.
Frequently Asked Questions About positive regulation of Notch signaling pathway
What is GO:0045747 positive regulation of Notch signaling pathway?
GO:0045747 is a biological process term describing any process that activates or increases the frequency, rate or extent of the Notch signaling pathway.
What genes are involved in positive regulation of Notch signaling?
Key genes include NOTCH1, ADAM17, RBPJ, TRIM59, GRWD1, MAML1, DLL1, DLL4, JAG1, and JAG2.
How does GRWD1 activate Notch signaling?
GRWD1 overexpression up-regulates ADAM17, which cleaves NOTCH and activates Notch signaling in gastric cancer.
What is the role of TRIM59 in Notch signaling?
TRIM59 forms a positive feedback circuit with RBPJ to activate Notch signaling and confer gemcitabine resistance in pancreatic cancer.
How is Notch signaling linked to CD8+ T cell exhaustion?
Notch signaling regulates CD8+ T cell activation and exhaustion, with implications for antitumor immunity in hepatocellular carcinoma.
Can CRISPR knockout be used to study Notch signaling?
Yes, CRISPR knockout of GRWD1 or TRIM59 reduces Notch activation, validating their causal roles.
What diseases are associated with positive regulation of Notch signaling?
Gastric cancer, pancreatic cancer, hepatocellular carcinoma, Epstein-Barr virus-induced infectious mononucleosis, and alloreactivity.
How does Notch signaling affect early pregnancy?
Notch signaling pathway members are dynamically expressed during early pregnancy in mice, indicating a role in embryo implantation.
What happens when Notch signaling is down-regulated in lung cancer?
Down-regulation induces caspase-dependent and caspase-independent apoptosis in lung squamous cell carcinoma cells.
What experimental models are used to study positive regulation of Notch signaling?
CRISPR knockout, point mutation, knock-in, overexpression cell models, and CRISPR library screening.
Conclusion
GO:0045747 positive regulation of Notch signaling pathway is a critical biological process that amplifies a conserved cell-cell communication system. Its dysregulation drives cancer progression, chemoresistance, and immune dysfunction, as demonstrated by GRWD1-ADAM17 and TRIM59/RBPJ mechanisms. Understanding these positive regulatory events provides opportunities for therapeutic intervention. CRISPR-based cell models and functional genomics are indispensable for dissecting causal roles and identifying new targets in Notch signaling research.
References
- 1. Ding H et al.. 2024. GRWD1 Over-Expression Promotes Gastric Cancer Progression by Activating Notch Signaling Pathway via Up-Regulation of ADAM17.. Dig Dis Sci 69(3):821-834 PMID: 38172445
- 2. Pu Q et al.. 2024. Prognostic value of CD8(+)T cells related genes and exhaustion regulation of Notch signaling pathway in hepatocellular carcinoma.. Front Immunol 15:1375864 PMID: 38650927
- 3. Tsukumo SI et al.. 2018. Regulation of CD8(+) T Cells and Antitumor Immunity by Notch Signaling.. Front Immunol 9:101 PMID: 29441071
- 4. Chen S et al.. 2024. TRIM59/RBPJ positive feedback circuit confers gemcitabine resistance in pancreatic cancer by activating the Notch signaling pathway.. Cell Death Dis 15(12):932 PMID: 39725730
- 5. Li Y et al.. 2024. [The Role of Notch Signaling Pathway in Adult Patients with Epstein-Barr Virus-induced Infectious Mononucleosis].. Zhongguo Shi Yan Xue Ye Xue Za Zhi 32(3):920-926 PMID: 38926989
- 6. Radojcic V et al.. 2016. Notch Signaling and Alloreactivity.. Transplantation 100(12):2593-2600 PMID: 27607530
- 7. Acar N et al.. 2023. Expressions of Notch signalling pathway members during early pregnancy in mice.. J Mol Histol 54(4):297-312 PMID: 37344690
- 8. Cao H et al.. 2012. Down-regulation of Notch receptor signaling pathway induces caspase-dependent and caspase-independent apoptosis in lung squamous cell carcinoma cells.. APMIS 120(6):441-50 PMID: 22583356
